Experimental Two-Drug attack on Tough-to-Treat colon cancer
NCT ID NCT07490119
Summary
This study is testing whether a new drug called becotatug vedotin, when combined with an existing drug (cetuximab), can help control advanced colorectal cancer that has stopped responding to other treatments. It will involve about 31 adults whose cancer has a specific genetic profile (RAS wild-type) and has spread. The main goal is to see if the combination shrinks tumors and for how long.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RAS WILD TYPE MCRC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.